COVID19, Public Policy, Health Policy, mRNA Vaccines, Vaccines, Clinical Trial Design, Evidence Hierarchy
This is a FOIA document of the first 2.5 months after the vaccine roll-out. Discuss clinical trial design and hierarchy of evidence in context of mRNA vaccines.
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021
Pfizer Adverse Events Report
Source: https://www.datascienceassn.org/content/pfizer-adverse-events-report